Dicycloverine hydrochloride oral
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulations of dicycloverine hydrochloride.
Adjunct in gastric smooth muscle spasm
10 to 20mg three times per day.
Dicycloverine is contraindicated in infants under 6 months of age.
Children aged 12 to 18 years
10 to 20mg three times per day.
Children aged 2 to 12 years
10mg three times per day.
Children aged 6 months to 2 years
5 to 10mg three to four times per day.
Give 15 minutes before feeds. Maximum daily dose of 40mg.
Children under 6 months
Precautions and Warnings
Predisposition to narrow angle glaucoma
Benign prostatic hyperplasia
Glucose-galactose malabsorption syndrome
Hereditary fructose intolerance
Narrow angle glaucoma
Some formulations contain glucose
Some formulations contain lactose
Some formulations contain sucrose
Pregnancy and Lactation
Use dicycloverine with caution during pregnancy.
The manufacturer recommends that dicycloverine is not used in pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Animal studies have demonstrated no evidence of impaired fertility or adverse foetal effects with dicycloverine. Epidemiological studies on the use of dicycloverine in human pregnancies have also indicated that dicycloverine hydrochloride does not appear to increase the risk of foetal abnormalities if administered during the first trimester of pregnancy.
Use dicycloverine with caution during breastfeeding.
The manufacturer recommends that caution is exercised when dicycloverine is administered during breastfeeding and state that it is unknown whether dicycloverine is secreted in human milk.
Decreased bronchial secretions
Difficulty in micturition
Dilatation of pupils
Disturbances in accommodation
Glaucoma (closed angle)
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: August 2014
Summary of Product Characteristics: Dicycloverine 10mg tablets. Zentiva. Revised April 2014.
Summary of Product Characteristics: Dicycloverine 10mg/5ml oral solution. Zentiva. Revised May 2014.
Summary of Product Characteristics: Dicycloverine 20mg tablets. Zentiva. Revised April 2014.
Summary of Product Characteristics: Dicycloverine Hydrochloride 10mg/5ml Oral Solution. Noumed Life Sciences Limited. Revised October 2019.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 08 September 2022
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.